OCT market to hit $800 million by 2012

Article

By 2012 the market for optical coherence tomography (OCT) is predicted to hit the $800 million mark.

By 2012 the market for optical coherence tomography (OCT) is predicted to hit the $800 million mark, according to a recent market research report.

The report, "Optical Coherence Tomography - Technology, markets and applications: 2008-2021", from the publishers of BioOptics World quantifies this rapidly growing market for the first time. Currently the global market for OCT systems is around $200 million and is growing at an annual rate of 34%.

It is expected that the first commercial application of OCT, ophthalmology, will remain the dominant application until 2012, however, new applications and products are beginning to emerge in cardiology, dentistry, cancer detection, glucose monitoring and dermatology. In particular, commercial activity for OCT in intravascular imaging has been gaining momentum over the past 12 months.

Much of this recent activity in the market is being driven by a shift from time-domain to Fourier-domain OCT. While similar, Fourier-domain systems offer twice the resolution and 50 to 100 times the image-acquisition speed. Furthermore, because the Fourier-domain technique is not protected under tightly held patents, more companies are able to develop or market products using the technology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.